Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 17Recruiting 15Active not recruiting 8Terminated 5Withdrawn 3Unknown 3Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Eyelid Squamous Cell Carcinoma 1

Interventions

Specimen Handling 34Magnetic Resonance Spectroscopy 22Biopsy 20Cyclophosphamide 16Nivolumab 10Paclitaxel 9Cisplatin 9Gemcitabine 8Bevacizumab 8venetoclax 7Vincristine 7Prednisone 7Doxorubicin 7Azacitidine 7pembrolizumab 6Radiotherapy 6Radiosurgery 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Taxes 5Surgical Procedures, Operative 5Rituximab 5Oxaliplatin 5Irinotecan 5Everolimus 5Capecitabine 5fludarabine phosphate 4fludarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Radiotherapy, Image-Guided × Clear all
NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI)

Phase 3 Suspended
420 enrolled
DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡